GSK plc Price & Performance (GSK)

GSK has achieved key regulatory wins, including UK approval for its blood cancer therapy Blenrep and U.S. FDA acceptance of depemokimab for asthma. Positive recommendations for its vaccines further enhance its portfolio. These advances, paired with ongoing share buybacks, have strengthened investor sentiment and highlighted the company’s commitment to innovation.12

GSK has ramped up its share repurchase activity, buying more than 30 million shares since February 24, 2025, increasing treasury holdings and signaling confidence in future growth. The company’s active capital return strategy comes amid robust product approvals and a focus on shareholder value.23

While GSK’s stock has rebounded from recent lows and garnered moderate buy consensus among analysts, concerns over valuation persist. The company’s P/E and P/B ratios suggest it may be trading above sector averages, prompting a measured outlook even as product and regulatory successes support its near-term prospects.45